Efficacy and Safety of Allium Ureteral Stent for Treating Refractory Ureteral Stricture
- Conditions
- HydronephrosisUreteral Stent OcclusionUreteral Stenosis
- Interventions
- Device: Allium ureteral stent
- Registration Number
- NCT05455307
- Lead Sponsor
- En Chu Kong Hospital
- Brief Summary
To conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.
- Detailed Description
The aim of the study is to conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.
About 200 participants with refractory ureteral stricture will be enrolled in four hospitals. After the allium ureteral stents are placed, renal function, renal echo, images and associated complications will be recorded.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- refractory ureteral stricture after at least two times of ureteral dilation
- poor cardiovascular function for anesthesia unwilling to accept the long-term placement of ureteral stent uncontrolled urinary tract infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description single arm Allium ureteral stent single arm without placebo control
- Primary Outcome Measures
Name Time Method Renal function test 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months serum creatinine (mg/dL)
- Secondary Outcome Measures
Name Time Method Renal structure 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months Renal echo (e.g. no hydronephrosis, mild hydronephrosis, moderate hydronephrosis, orsevere hydronephrosis)
Complications 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months device associated complications (e.g. urinary tract infection, stone formation, hematuria, stent migration)
Trial Locations
- Locations (1)
En Chu Kong Hospital
🇨🇳New Taipei City, Taiwan